| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/17/2005 | WO2005023311A2 Novel targets for the treatment of retina diseases |
| 03/17/2005 | WO2005023308A1 Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins |
| 03/17/2005 | WO2005023298A1 A method selecting an immunotherapeutic preparation |
| 03/17/2005 | WO2005023296A1 Treatment of rheumatic diseases |
| 03/17/2005 | WO2005023293A1 Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere |
| 03/17/2005 | WO2005023292A1 Methods of treating restenosis |
| 03/17/2005 | WO2005023291A2 Use of glp1-agonists in the treatment of patients with type i diabetes |
| 03/17/2005 | WO2005023290A2 Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections |
| 03/17/2005 | WO2005023289A1 Medicinal composition for treating chronic hepatitis c |
| 03/17/2005 | WO2005023288A1 Treatment of fibrotic disease |
| 03/17/2005 | WO2005023287A1 Skin ulcer preventive curative agent containing human recombinant hgf |
| 03/17/2005 | WO2005023286A1 Medical agent for prevention and/or treatment of alzheimer disease |
| 03/17/2005 | WO2005023285A2 Agent and method for the treatment and prevention of tse and method for the production of said agent |
| 03/17/2005 | WO2005023284A1 Ion channel modulators |
| 03/17/2005 | WO2005023283A1 Ophthalmic composition |
| 03/17/2005 | WO2005023282A1 Nanoparticle containing physiologically active protein or peptide, process for producing the same and external preparation comprising the nanoparticle |
| 03/17/2005 | WO2005023276A1 Pharmaceutical active agent against breast cancer |
| 03/17/2005 | WO2005023275A1 Pharmaceutical active ingredient against hepatitis |
| 03/17/2005 | WO2005023264A1 Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate |
| 03/17/2005 | WO2005023250A1 Use of telmisartan for the prevention of vascular headache |
| 03/17/2005 | WO2005023232A2 Therapeutic, screening and diagnostic methods based on the effect of cb1 receptor modulation on lymphoproliferative disorders. |
| 03/17/2005 | WO2005023231A1 Polypyrimidine tract binding protein promotes insulin secretory granule biogenesis |
| 03/17/2005 | WO2005023195A2 Treatment of spinal cord injury |
| 03/17/2005 | WO2005023193A2 Methods of treating endometriosis |
| 03/17/2005 | WO2005023190A2 Treatment for cd5+ b cell lymphoma |
| 03/17/2005 | WO2005023176A2 Delivery of physiologixal agents with in-situ gels comprising anionic polysaccharides |
| 03/17/2005 | WO2005023017A1 Food composition |
| 03/17/2005 | WO2005014032A3 Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite |
| 03/17/2005 | WO2005014026A3 Use of cxcl6 chemokine in the prevention or repair of cartilage defects |
| 03/17/2005 | WO2005007184A3 Cyclic analogs of human parathyroid hormone for the treatment of conditions characterized by hyperproliferative skin cells |
| 03/17/2005 | WO2005004838A8 Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof |
| 03/17/2005 | WO2004113378A3 Control of lactation and peptides therefore |
| 03/17/2005 | WO2004111078A3 Compounds that modulate the glucagon response and uses thereof |
| 03/17/2005 | WO2004108761A3 Canine ghrh gene, polypeptides and methods of use |
| 03/17/2005 | WO2004105781A3 Stabilized pharmaceutical peptide compositions |
| 03/17/2005 | WO2004103297A3 Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis |
| 03/17/2005 | WO2004098626A8 The use of a polypeptide domain of slpi to modulate the tumorigenic and metastatic potential of cancer cells |
| 03/17/2005 | WO2004096856A3 Secreted protein family |
| 03/17/2005 | WO2004096266A8 Improved physical stability of insulin formulations |
| 03/17/2005 | WO2004094589A3 Secreted proteins |
| 03/17/2005 | WO2004089376A3 Identification and targeting of consensus sites by which dynorphin exerts its neurotoxic effects enables analgesia without neurotoxicity |
| 03/17/2005 | WO2004087213A8 Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant |
| 03/17/2005 | WO2004083404A3 Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain |
| 03/17/2005 | WO2004083383A3 Globin variant gene methods and compositions |
| 03/17/2005 | WO2004083243A8 Amylin aggregation inhibitors and use thereof. |
| 03/17/2005 | WO2004082708A3 Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides |
| 03/17/2005 | WO2004082608A9 Ligands for tgf-beta binding proteins and uses thereof |
| 03/17/2005 | WO2004080287A3 Method of killing cancer cells |
| 03/17/2005 | WO2004076619A3 New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
| 03/17/2005 | WO2004076473A3 Androgen receptor interacting peptides |
| 03/17/2005 | WO2004075843A3 Glycosolated enkephalin agents |
| 03/17/2005 | WO2004074461A3 Production of modified glycoproteins having multiple antennary structures |
| 03/17/2005 | WO2004069223A3 Pharmaceutical compositions comprising immunosuppressants and uses thereof |
| 03/17/2005 | WO2004069165A3 Methods and compositions for the treatment of gastrointestinal disorders |
| 03/17/2005 | WO2004061081A3 Sirna compounds and methods for the downregulation of gene expression |
| 03/17/2005 | WO2004060291A3 Uses of mammalian cytokine; related reagents |
| 03/17/2005 | WO2004058815A3 Centrosome-associated protein and applications thereof |
| 03/17/2005 | WO2004056862A3 Immunogenic compositions to the cck-b/gastrin receptor and methods for the treatment of tumors |
| 03/17/2005 | WO2004050846A3 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines |
| 03/17/2005 | WO2004043486A8 An acqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboembolism |
| 03/17/2005 | WO2004038416A8 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 6 (gpr6) |
| 03/17/2005 | WO2004032850A3 Uses of human zven antagonists |
| 03/17/2005 | WO2004019761A3 Methods of treating age-related defects and diseases |
| 03/17/2005 | WO2004016761A3 Gene therapy for critical limb ischemia with wild type or mutant enos |
| 03/17/2005 | WO2003104429B1 Genes overexpressed by ovarian cancer and their use in developing novel therapeutics |
| 03/17/2005 | WO2003101484A9 Compositions and methods for transepithelial molecular transport |
| 03/17/2005 | WO2003092614A3 Lipid removal from the body |
| 03/17/2005 | WO2003061564A8 Gene expression profiles in liver disease |
| 03/17/2005 | WO2003051835A3 Methods and compositions for the inhibition of viral release |
| 03/17/2005 | WO2003039578A8 Treatment of congestive heart failure |
| 03/17/2005 | WO2003016489A8 Porcine leptin protein, antisense and antibody |
| 03/17/2005 | WO2003011898A3 Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses |
| 03/17/2005 | WO2002100343A3 N-terminally truncated galectin-3 and antibodies for treating cancer |
| 03/17/2005 | WO2002079227A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/17/2005 | WO2002074156A8 Compositions and methods for the therapy and diagnosis of colon cancer |
| 03/17/2005 | US20050060770 Antifungal proteins |
| 03/17/2005 | US20050060761 Using tetanus toxin/reporter protein fusion as diagnstic tool in detection, monitoring and diagnosis of neurodegenerative disease |
| 03/17/2005 | US20050059816 Novel human protease inhibitor proteins and polynucleotides encoding the same |
| 03/17/2005 | US20050059807 Transcriptional modulator for use in the treatment and prevention of cell proliferative, muscular, blood, gastrointestinal and cardiovascular disorders |
| 03/17/2005 | US20050059806 Expression vector comprising nucleotide sequences coding immunoglobulins for use in the treatment and prevention of asthma, food allergies, hypersensitivity and anaphylactic reactions; immunotherapy |
| 03/17/2005 | US20050059802 chimeric peptide of a peptide wherein the carboxyl terminus of the first portion (comprising a naturally-occurring internal peptide cleavage product) is linked to the amino terminus of the second portion (comprising a T helper cell epitope) |
| 03/17/2005 | US20050059742 Such as 5-butyl-2,4-dihydro-4-[[2'-[N-(3-chloro-2-thiophenecarbonyl)sulfamoyl]biphenyl-4-yl]methyl]-2-{2-(trifluoromethyl)phenyl]-1,2,4-triazol-3-one potassium salt, or a prostaglandin derivative, or 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid (AH 6809) |
| 03/17/2005 | US20050059699 N-acylated lipophilic amino acid derivatives |
| 03/17/2005 | US20050059689 Therapy for stroke, cancer, multiple sclerosis, brain disorders, Parkinson's disease, Huntington's diseasee |
| 03/17/2005 | US20050059647 Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus |
| 03/17/2005 | US20050059631 Lowering circulating free fatty acid levels in an individual by administering purified, isolated, or recombinant OBG3 or gOBG3 polypeptide fragment that has significantly greater activity than a full-length OBG3 polypeptide; treatment of hyperlipidemias, atherosclerosis, diabetes, and hypertension |
| 03/17/2005 | US20050059630 TTK in diagnosis and as a therapeutic target in cancer |
| 03/17/2005 | US20050059629 Antisense modulation of connective tissue growth factor expression |
| 03/17/2005 | US20050059627 Administering antisense oligonucleotides against the mRNA of corticotropin releasing factor subtype-2 (CRF2) receptor; treating anxiety, obsessive-compulsive disorder, panic disorders, post-traumatic stress, phobias and depression |
| 03/17/2005 | US20050059624 Application of mRNA for use as a therapeutic against tumour diseases |
| 03/17/2005 | US20050059623 linking chaperone protein promoters to genetically engineered genes, then heating |
| 03/17/2005 | US20050059622 Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression |
| 03/17/2005 | US20050059618 Men protein, gst2, rab-rp1, csp, f-box protein lilina/fbl7, abc50, coronin, sec61 alpha, or vhappa1-1, or homologous proteins involved in the regulation of energy homeostasis |
| 03/17/2005 | US20050059617 Novel anitsense oligonucleotide derivatives against to hepatitis c virus |
| 03/17/2005 | US20050059610 Glutamine for use in treating injury |
| 03/17/2005 | US20050059609 New alpha crystalline form of perindopril tert-butylamine salt |
| 03/17/2005 | US20050059607 Process for preparing peptidyl heterocyclic ketone derivatives |
| 03/17/2005 | US20050059606 hexapeptides including enantiomers, stereoisomers and tautomers, used as enzyme inhibitors for prophylaxis or prevention of viral diseases |
| 03/17/2005 | US20050059604 A GPCR-like protein for treating glaucoma |
| 03/17/2005 | US20050059603 Compounds which prevent neuronal cell death and uses thereof |